Stocktoria
Aclarion, Inc. ACON
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2022-04-22
Aclarion, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 9.0% | -85.2% | -0.4% | -8.0% | -14.7% |
| Operating margin | -9312.5% | -12057.2% | -6466.5% | -9201.2% | -4897.9% |
| Net margin | -9551.9% | -15293.8% | -6513.4% | -11694.4% | -8210.5% |
| FCF margin | -9488.6% | -11540.4% | -4836.5% | — | — |
| Return on assets | -52.9% | -329.3% | -199.7% | -242.5% | -262.0% |
| Return on equity | -56.4% | -720.9% | 674.6% | -317.6% | 38.6% |
| Current ratio | 14.81 | 0.71 | 0.40 | 2.47 | 0.10 |
| Revenue growth | 65.6% | -39.4% | 24.8% | 0.3% | — |
Source: SEC EDGAR filings · CIK 0001635077 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.